{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T17:37:54Z","timestamp":1791999474419,"version":"4.4.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,1,2]],"date-time":"2020-01-02T00:00:00Z","timestamp":1577923200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,1,2]],"date-time":"2020-01-02T00:00:00Z","timestamp":1577923200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003554","name":"Lundbeck Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003554","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Danish Council of Independent Research"},{"name":"Olav Thon Foundation"},{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"crossref"}]},{"name":"European Research Council"},{"name":"NEURODIN, Aarhus University Research Foundation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Plasma and cerebrospinal fluid levels of neurofilament light (NfL), a marker of axonal degeneration, have previously been reported to be raised in patients with clinically diagnosed Alzheimer\u2019s disease (AD). Activated microglia, an intrinsic inflammatory response to brain lesions, are also known to be present in a majority of Alzheimer or mild cognitive\u00a0impaired (MCI) subjects with raised \u03b2-amyloid load on their positron emission tomography (PET) imaging. It is now considered that the earliest phase of inflammation may be protective to the brain, removing amyloid plaques and remodelling synapses. Our aim was to determine whether the cortical inflammation\/microglial activation load, measured with the translocator protein marker\n                      <jats:sup>11<\/jats:sup>\n                      C-PK11195 PET, was correlated with plasma NfL levels in prodromal and early Alzheimer subjects.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Twenty-seven MCI or early AD cases with raised cortical \u03b2-amyloid load had\n                      <jats:sup>11<\/jats:sup>\n                      C-\n                      <jats:italic>(R)<\/jats:italic>\n                      -PK11195 PET, structural and diffusion magnetic resonance imaging, and levels of their plasma NfL measured. Correlation analyses were performed using surface-based cortical statistics.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Statistical maps localised areas in MCI cases where levels of brain inflammation correlated inversely with plasma NfL levels. These areas were localised in the frontal, parietal, precuneus, occipital, and sensorimotor cortices. Brain inflammation correlated negatively with mean diffusivity (MD) of water with regions overlapping.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>We conclude that an inverse correlation between levels of inflammation in cortical areas and plasma NfL levels indicates that microglial activation may initially be protective to axons in AD. This is supported by the finding of an inverse association between cortical water diffusivity and microglial activation in the same regions. Our findings suggest a rationale for stimulating microglial activity in early and prodromal Alzheimer cases\u2014possibly using immunotherapy. Plasma NfL levels could be used as a measure of the protective efficacy of immune stimulation and for monitoring efficacy of putative neuroprotective agents.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13195-019-0574-0","type":"journal-article","created":{"date-parts":[[2020,1,2]],"date-time":"2020-01-02T14:04:35Z","timestamp":1577973875000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Low plasma neurofilament light levels associated with raised cortical microglial activation suggest inflammation acts to protect prodromal Alzheimer\u2019s disease"],"prefix":"10.1186","volume":"12","author":[{"given":"Peter","family":"Parbo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lasse Stensvig","family":"Madsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rola","family":"Ismail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaj","family":"Blennow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon F.","family":"Eskildsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Vorup-Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Brooks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,2]]},"reference":[{"key":"574_CR1","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1083\/jcb.66.2.351","volume":"66","author":"PN Hoffman","year":"1975","unstructured":"Hoffman PN, Lasek RJ. The slow component of axonal transport: identification of major structural polypeptides of the axon and their generality among mammalian neurons. J Cell Biol. 1975;66:351\u201366. https:\/\/doi.org\/10.1083\/jcb.66.2.351.","journal-title":"J Cell Biol"},{"key":"574_CR2","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1046\/j.1471-4159.1996.67052013.x","volume":"67","author":"LE Rosengren","year":"1996","unstructured":"Rosengren LE, Karlsson JE, Karlsson JO, Persson LI, Wikkels\u00f8 C. Patients with amyotrophic lateral sclerosis and other neurodegenerative diseases have increased levels of neurofilament protein in CSF. J Neurochem. 1996;67:2013\u20138. https:\/\/doi.org\/10.1046\/j.1471-4159.1996.67052013.x.","journal-title":"J Neurochem"},{"key":"574_CR3","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1080\/21678421.2017.1281962","volume":"18","author":"T Skillb\u00e4ck","year":"2017","unstructured":"Skillb\u00e4ck T, Mattsson N, Blennow K, Zetterberg H. Cerebrospinal fluid neurofilament light concentration in motor neuron disease and frontotemporal dementia predicts survival. Amyotroph Lateral Scler Front Degener. 2017;18:397\u2013403. https:\/\/doi.org\/10.1080\/21678421.2017.1281962.","journal-title":"Amyotroph Lateral Scler Front Degener"},{"key":"574_CR4","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1212\/WNL.0b013e3181a0fe3f","volume":"72","author":"CE Teunissen","year":"2009","unstructured":"Teunissen CE, Iacobaeus E, Khademi M, Brundin L, Norgren N, Koel-Simmelink MJA, et al. Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosis. Neurology. 2009;72:1322\u20139. https:\/\/doi.org\/10.1212\/WNL.0b013e3181a0fe3f.","journal-title":"Neurology"},{"key":"574_CR5","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1007\/s00415-004-0451-y","volume":"251","author":"A Olsson","year":"2004","unstructured":"Olsson A, Csajbok L, \u00d6st M, H\u00f6glund K, Nyl\u00e9n K, Rosengren L, et al. Marked increase of beta-amyloid(1-42) and amyloid precursor protein in ventricular cerebrospinal fluid after severe traumatic brain injury. J Neurol. 2004;251:870\u20136. https:\/\/doi.org\/10.1007\/s00415-004-0451-y.","journal-title":"J Neurol"},{"key":"574_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0172762","volume":"12","author":"V Niemel\u00e4","year":"2017","unstructured":"Niemel\u00e4 V, Landtblom AM, Blennow K, Sundblom J. Tau or neurofilament light-which is the more suitable biomarker for Huntington\u2019s disease? PLoS One. 2017;12:1\u201311. https:\/\/doi.org\/10.1371\/journal.pone.0172762.","journal-title":"PLoS One"},{"key":"574_CR7","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.ebiom.2015.11.036","volume":"3","author":"M Gissl\u00e9n","year":"2016","unstructured":"Gissl\u00e9n M, Price RW, Andreasson U, Norgren N, Nilsson S, Hagberg L, et al. Plasma concentration of the neurofilament light protein (NFL) is a biomarker of CNS injury in HIV infection: a cross-sectional study. EBioMedicine. 2016;3:135\u201340. https:\/\/doi.org\/10.1016\/j.ebiom.2015.11.036.","journal-title":"EBioMedicine"},{"key":"574_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neuron.2016.06.030","volume":"91","author":"H Zetterberg","year":"2016","unstructured":"Zetterberg H. Neurofilament light: a dynamic cross-disease fluid biomarker for Neurodegeneration. Neuron. 2016;91:1\u20133. https:\/\/doi.org\/10.1016\/j.neuron.2016.06.030.","journal-title":"Neuron"},{"key":"574_CR9","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1212\/WNL.0000000000004667","volume":"89","author":"PSJ Weston","year":"2017","unstructured":"Weston PSJ, Poole T, Ryan NS, Nair A, Liang Y, Macpherson K, et al. Serum neurofilament light in familial Alzheimer disease: a marker of early neurodegeneration. Neurology. 2017;89:2167\u201375. https:\/\/doi.org\/10.1212\/WNL.0000000000004667.","journal-title":"Neurology"},{"key":"574_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13195-018-0404-9","volume":"10","author":"P Lewczuk","year":"2018","unstructured":"Lewczuk P, Ermann N, Andreasson U, Schultheis C, Podhorna J, Spitzer P, et al. Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer\u2019s disease. Alzheimers Res Ther. 2018;10:1\u201310. https:\/\/doi.org\/10.1186\/s13195-018-0404-9.","journal-title":"Alzheimers Res Ther"},{"key":"574_CR11","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1001\/jamaneurol.2016.6117","volume":"74","author":"N Mattsson","year":"2017","unstructured":"Mattsson N, Andreasson U, Zetterberg H, Blennow K, Weiner MW, Aisen P, et al. Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease. JAMA Neurol. 2017;74:557\u201366. https:\/\/doi.org\/10.1001\/jamaneurol.2016.6117.","journal-title":"JAMA Neurol"},{"key":"574_CR12","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/0166-2236(96)10049-7","volume":"19","author":"GW Kreutzberg","year":"1996","unstructured":"Kreutzberg GW. Microglia: a sensor for pathological events in the CNS. Trends Neurosci. 1996;19:312\u20138. https:\/\/doi.org\/10.1016\/0166-2236(96)10049-7.","journal-title":"Trends Neurosci"},{"key":"574_CR13","doi-asserted-by":"publisher","first-page":"355","DOI":"10.3233\/JAD-2010-1219","volume":"19","author":"EG McGeer","year":"2010","unstructured":"McGeer EG, McGeer PL. Neuroinflammation in Alzheimer\u2019s disease and mild cognitive impairment: a field in its infancy. J Alzheimers Dis. 2010;19:355\u201361. https:\/\/doi.org\/10.3233\/JAD-2010-1219.","journal-title":"J Alzheimers Dis"},{"key":"574_CR14","doi-asserted-by":"publisher","first-page":"677","DOI":"10.2967\/jnumed.110.086629","volume":"52","author":"AM Scarf","year":"2011","unstructured":"Scarf AM, Kassiou M. The Translocator protein. J Nucl Med. 2011;52:677\u201380. https:\/\/doi.org\/10.2967\/jnumed.110.086629.","journal-title":"J Nucl Med"},{"key":"574_CR15","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1093\/brain\/awx120","volume":"140","author":"P Parbo","year":"2017","unstructured":"Parbo P, Ismail R, Hansen KV, Amidi A, M\u00e5rup FH, Gottrup H, et al. Brain inflammation accompanies amyloid in the majority of mild cognitive impairment cases due to Alzheimer\u2019s disease. Brain. 2017;140:2002\u201311. https:\/\/doi.org\/10.1093\/brain\/awx120.","journal-title":"Brain"},{"key":"574_CR16","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1212\/01.wnl.0000244749.20056.d4","volume":"68","author":"P Edison","year":"2007","unstructured":"Edison P, Archer H, Hinz R, Hammers A, Tai Y, Hotton G, et al. Amyloid, hypometabolism, and cognition in Alzheimer disease. An [ 11C ]PIB and [18F ]FDG PET study. Neurology. 2007;68:501\u20138.","journal-title":"Neurology"},{"key":"574_CR17","doi-asserted-by":"publisher","unstructured":"Fan Z, Brooks DJ, Okello A, Edison P. An early and late peak in microglial activation in Alzheimer\u2019s disease trajectory. Brain 2017:aww349. doi:https:\/\/doi.org\/10.1093\/brain\/aww349.","DOI":"10.1093\/brain\/aww349"},{"key":"574_CR18","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1002\/mrm.24743","volume":"69","author":"B Hansen","year":"2013","unstructured":"Hansen B, Lund TE, Sangill R, Jespersen SN. Experimentally and computationally fast method for estimation of a mean kurtosis. Magn Reson Med. 2013;69:1754\u201360. https:\/\/doi.org\/10.1002\/mrm.24743.","journal-title":"Magn Reson Med"},{"issue":"6","key":"574_CR19","doi-asserted-by":"publisher","first-page":"2250","DOI":"10.1002\/mrm.25090","volume":"71","author":"Brian Hansen","year":"2014","unstructured":"Hansen B, Lund TE, Sangill R, Jespersen SN. Erratum: Hansen, Lund, Sangill, and Jespersen. Experimentally and computationally fast method for estimation of a mean kurtosis (Magnetic Resonance in Medicine 69:1754\u20131760 (2013). Magn Reson Med 2014;71:2250. doi:https:\/\/doi.org\/10.1002\/mrm.25090.","journal-title":"Magnetic Resonance in Medicine"},{"key":"574_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13195-015-0132-3","volume":"7","author":"PSJ Weston","year":"2015","unstructured":"Weston PSJ, Simpson IJA, Ryan NS, Ourselin S, Fox NC. Diffusion imaging changes in grey matter in Alzheimer\u2019s disease: a potential marker of early neurodegeneration. Alzheimers Res Ther. 2015;7:1\u20138. https:\/\/doi.org\/10.1186\/s13195-015-0132-3.","journal-title":"Alzheimers Res Ther"},{"key":"574_CR21","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.nbd.2018.06.004","volume":"117","author":"P Parbo","year":"2018","unstructured":"Parbo P, Ismail R, Sommerauer M, Stokholm MG, Hansen AK, Hansen KV, et al. Does inflammation precede tau aggregation in early Alzheimer\u2019s disease? A PET study. Neurobiol Dis. 2018;117:211\u20136. https:\/\/doi.org\/10.1016\/j.nbd.2018.06.004.","journal-title":"Neurobiol Dis"},{"key":"574_CR22","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1006\/nimg.1996.0066","volume":"4","author":"AA Lammertsma","year":"1996","unstructured":"Lammertsma AA, Hume SP. Simplified reference tissue model for PET receptor studies. Neuroimage. 1996;4:153\u20138. https:\/\/doi.org\/10.1006\/nimg.1996.0066.","journal-title":"Neuroimage"},{"key":"574_CR23","first-page":"158","volume":"48","author":"FE Turkheimer","year":"2007","unstructured":"Turkheimer FE, Edison P, Pavese N, Roncaroli F, Anderson AN, Hammers A, et al. Reference and target region modeling of [11C]-(R)-PK11195 brain studies. J Nucl Med. 2007;48:158\u201367.","journal-title":"J Nucl Med"},{"key":"574_CR24","first-page":"823","volume":"9","author":"SF Eskildsen","year":"2006","unstructured":"Eskildsen SF, \u00d8stergaard LR. Active surface approach for extraction of the human cerebral cortex from MRI. Med Image Comput Comput Interv. 2006;9:823\u201330.","journal-title":"Med Image Comput Comput Interv"},{"key":"574_CR25","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.neuroimage.2010.07.033","volume":"54","author":"V Fonov","year":"2011","unstructured":"Fonov V, Evans AC, Botteron K, Almli CR, McKinstry RC, Collins DL. Unbiased average age-appropriate atlases for pediatric studies. Neuroimage. 2011;54:313\u201327. https:\/\/doi.org\/10.1016\/j.neuroimage.2010.07.033.","journal-title":"Neuroimage"},{"key":"574_CR26","doi-asserted-by":"publisher","unstructured":"Eskildsen SF, \u00d8stergaard LR. Evaluation of five algorithms for mapping brain cortical surfaces. Proc - 21st Brazilian Symp Comput Graph Image Process 2008:137\u201344. doi:https:\/\/doi.org\/10.1109\/SIBGRAPI.2008.16.","DOI":"10.1109\/SIBGRAPI.2008.16"},{"key":"574_CR27","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1002\/hbm.460010306","volume":"1","author":"KJ Friston","year":"1994","unstructured":"Friston KJ, Worsley KJ, Frackowiak RSJ, Mazziotta JC, Evans AC. Assessing the significance of focal activations using their spatial extent. Hum Brain Mapp. 1994;1:210\u201320. https:\/\/doi.org\/10.1002\/hbm.460010306.","journal-title":"Hum Brain Mapp"},{"key":"574_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fninf.2019.00014","volume":"13","author":"E Combrisson","year":"2019","unstructured":"Combrisson E, Vallat R, O\u2019Reilly C, Jas M, Pascarella A, Saive AL, et al. Visbrain: A multi-purpose GPU-accelerated open-source suite for multimodal brain data visualization. Front Neuroinform. 2019;13:1\u201314. https:\/\/doi.org\/10.3389\/fninf.2019.00014.","journal-title":"Front Neuroinform"},{"key":"574_CR29","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s40478-018-0649-3","volume":"7","author":"NJ Ashton","year":"2019","unstructured":"Ashton NJ, Leuzy A, Lim YM, Troakes C, Hortob\u00e1gyi T, H\u00f6glund K, et al. Increased plasma neurofilament light chain concentration correlates with severity of post-mortem neurofibrillary tangle pathology and neurodegeneration. Acta Neuropathol Commun. 2019;7:5. https:\/\/doi.org\/10.1186\/s40478-018-0649-3.","journal-title":"Acta Neuropathol Commun"},{"key":"574_CR30","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.neurobiolaging.2004.01.007","volume":"25","author":"RG Nagele","year":"2004","unstructured":"Nagele RG, Wegiel J, Venkataraman V, Imaki H, Wang KC, Wegiel J. Contribution of glial cells to the development of amyloid plaques in Alzheimer\u2019s disease. Neurobiol Aging. 2004;25:663\u201374. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2004.01.007.","journal-title":"Neurobiol Aging"},{"key":"574_CR31","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/S0197-4580(97)00056-0","volume":"18","author":"H Braak","year":"1997","unstructured":"Braak H, Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging. 1997;18:351\u20137. https:\/\/doi.org\/10.1016\/S0197-4580(97)00056-0.","journal-title":"Neurobiol Aging"},{"key":"574_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-018-35766-w","volume":"8","author":"YS Lin","year":"2018","unstructured":"Lin YS, Lee WJ, Wang SJ, Fuh JL. Levels of plasma neurofilament light chain and cognitive function in patients with Alzheimer or Parkinson disease. Sci Rep. 2018;8:1\u20138. https:\/\/doi.org\/10.1038\/s41598-018-35766-w.","journal-title":"Sci Rep"},{"key":"574_CR33","doi-asserted-by":"publisher","first-page":"7900","DOI":"10.1073\/pnas.1602413113","volume":"113","author":"A Eklund","year":"2016","unstructured":"Eklund A, Nichols TE, Knutsson H. Cluster failure: why fMRI inferences for spatial extent have inflated false-positive rates. Proc Natl Acad Sci U S A. 2016;113:7900\u20135. https:\/\/doi.org\/10.1073\/pnas.1602413113.","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-019-0574-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13195-019-0574-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-019-0574-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,31]],"date-time":"2020-12-31T19:28:59Z","timestamp":1609442939000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-019-0574-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,2]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["574"],"URL":"https:\/\/doi.org\/10.1186\/s13195-019-0574-0","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,2]]},"assertion":[{"value":"19 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The project was approved by the regional ethics committee, and all subjects gave their written informed consent.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All subjects involved and the authors gave their consent for publication of these findings.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"PP and RI declare that they have no competing interests. HZ has served on scientific advisory boards for Roche Diagnostics, Wave, Samumed, and CogRx and is a co-founder of Brain Biomarker Solutions in Gothenburg AB, a GU Ventures-based platform company at the University of Gothenburg (unrelated to the current study). TV-J has received a personal fee from Roche and research grants from the Danish Multiple Sclerosis Society (unrelated to the current study). DJB received research grants from the Danish Council for Independent Research and the Lundbeck Foundation during the conduct of the study. He is a Consultant for GE Healthcare and Biogen\u2122, and has served on Advisory Boards and received personal fees from AstraZeneca, Cytox, Shire, Novartis, GSK, Navidea, UCB, and Acadia. He has been awarded research grants and non-financial support from the Medical Research Council (UK), Alzheimer\u2019s Research Trust (UK), Michael J Fox Foundation, and the European Commission (unrelated to the current study).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3"}}